Response to ovarian stimulation is not impacted by a breast cancer diagnosis

Quinn, Molly M.; Çakmak, Hakan; Letourneau, Joseph M.; Cedars, Marcelle I.; Rosen, Mitchell P.

doi:10.1093/humrep/dew355

Cited by 52 publications

(78 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, a few studies have demonstrated a potential benefit of the use of the oral agent letrozole together with gonadotropin stimulation in IVF cycles, especially in breast cancer patients going through fertility preservation treatment 12 – 15 . The goal of co-administration of letrozole is to reduce serum estrogen concentrations during ovarian stimulation in breast cancer patients.…”

Section: Improving Oocyte Quality With New Stimulation and Triggeringmentioning

confidence: 99%

Recent advances in in vitro fertilization

et al. 2017

View full text Add to dashboard Cite

The field of assisted reproductive technology is rapidly progressing with many new advances in the last decade. The present review discusses methods to improve oocyte quality in older women and new stimulation protocols that may improve the number of mature oocytes retrieved during an in vitro fertilization cycle. We will discuss the present use of pre-implantation genetic screening (PGS) and finally focus on some new methods to determine endometrial receptivity. The focus of this review is to point out areas of technology that may be controversial or are new enough to require proper controlled studies for validation.

show abstract

Section: Improving Oocyte Quality With New Stimulation and Triggeringmentioning

confidence: 99%

Recent advances in in vitro fertilization

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Only two studies reported worse oocyte yield in comparison to women without cancer undergoing IVF ( Klock et al ., 2010 ; Domingo et al ., 2012 ). Quinn et al (2017) published a retrospective cohort analysis with 589 women (191 with breast cancer) who underwent COS. The group with breast cancer responded as well as the ones without cancer in terms of number of mature oocytes obtained.…”

Section: Resultsmentioning

confidence: 99%

Motherhood after breast cancer: can we balance fertility preservation and cancer treatment? A narrative review of the literature

Carneiro¹,

Cota²,

Amaral³

et al. 2018

JBRA Assisted Reproduction

View full text Add to dashboard Cite

Breast cancer may affect young women who have not yet completed childbearing. Assisted reproductive technology (ART) provides alternatives for fertility preservation such as oocyte, embryo or ovarian tissue cryopreservation. We reviewed the published literature on fertility-preserving management in breast cancer, aiming at finding evidence to answer the following questions: (1) What are the fertility sparing options available?; (2) How do these women respond to IVF? and (3) Can pregnancy influence breast cancer recurrence? There is a paucity of publications describing clinical experience and outcome data which limits accessibility to fertility preservation in this setting. Presently, oocyte or embryo cryopreservation are the main options for fertility preservation. IVF success rates are comparable to the ones of non-oncological populations according to the woman's age but current published studies lack data on definitive success rates following embryo banking for cancer patients. The perception that IVF and pregnancy may worsen cancer prognosis remains, despite the lack of scientific evidence to support this notion. Published studies show reassuring results for pregnancies occurring >2 years after breast cancer diagnosis. The best published evidence suggests pregnancy after breast cancer does not increase the risk of disease recurrence, thus pregnancy should not be forbidden once treatment is completed. Decision making for women diagnosed with cancer requires up-to-date knowledge of the efficacy and safety of available options. Providing consultation with a reproductive specialist and appropriate information on fertility preservation for these women should be an essential aspect of their supportive care.

show abstract

“…Despite the limited data on the efficacy of oocyte cryopreservation specifically in the oncological population, the response to controlled ovarian stimulation could be considered the same as the non-cancer population. 64 The success of oocyte/embryo cryopreservation is strongly dependent on the number of mature oocytes collected following controlled ovarian stimulation which is strongly influenced by the age and ovarian reserve of the patient at the time of the procedure. 65 The live birth rates using all cryopreserved oocytes after one stimulation cycle are around 35% in women <35 years.…”

Section: Fertility Preservation In Male Patients With Cancer Sperm Crmentioning

confidence: 99%

Gender-specific aspects related to type of fertility preservation strategies and access to fertility care

et al. 2020

View full text Add to dashboard Cite

Survivorship is an area of paramount importance to be addressed as early as possible after cancer diagnosis by all health care providers. On this regard, cancer care in young patients often poses several age-related considerations among which fertility and pregnancy-related issues have a crucial role. According to the available guidelines on the topic, all patients with cancer diagnosed during their reproductive years should be provided a proper oncofertility counselling before starting anticancer treatments. This is an important step in order to inform patients about the potential treatment-induced gonadotoxicity and the available strategies for fertility preservation so that they can be referred as early as possible to fertility specialists if potentially interested in these options.In this manuscript, we aim to provide an up to date overview on the available efficacy and safety data with the main strategies for fertility preservation in male and female cancer patients in order to help optimising the oncofertility counselling performed by healthcare providers involved in cancer care and dealing with young patients. In male patients with cancer, sperm cryopreservation is the standard technique for fertility preservation. Oocyte/embryo cryopreservation, ovarian tissue cryopreservation and temporary ovarian suppression with luteinising hormone-releasing hormone agonists during chemotherapy are the main options in female patients with cancer.A multidisciplinary management building a strong network between fertility and oncology/haematology units is crucial to properly address fertility care in all young patients with cancer, at both diagnosis and during oncologic follow-up. Discussing fertility and pregnancy-related issues with young patients with cancer has to be considered mandatory nowadays keeping in mind that returning to a normal life (including the possibility to have a family and to live with as few side effects as possible) should be considered an important ambition in cancer care in the 21st century .

show abstract

Response to ovarian stimulation is not impacted by a breast cancer diagnosis

Abstract: N/A.

Cited by 52 publications

References 36 publications

Recent advances in in vitro fertilization

Recent advances in in vitro fertilization

Motherhood after breast cancer: can we balance fertility preservation and cancer treatment? A narrative review of the literature

Gender-specific aspects related to type of fertility preservation strategies and access to fertility care

Contact Info

Product

Resources

About